Centene and its new pharmacy benefit manager partner RxAdvance are looking to deliver “disruption” and “unparalleled savings,” according to a Healthcare Dive report, but skepticism remains over the venture’s ability to compete.
While the 6-year-old PBM touts itself as more transparent than traditional companies, RxAdvance CEO Ravi Ika tells Healthcare Dive they are unable to divulge some details from its work with Centene.
“There are significant savings but we are unable to disclose it [to] the public because of restrictions,” he said.
Pembroke Consulting President Adam Fein tells Healthcare Dive he’s yet been able to discern what sets RxAdvance apart from other PBMs.
” … I haven’t been able to penetrate the Silicon Valley hype bubble either,” Fein said.